Article Text

Download PDFPDF
Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy
  1. Yuka Aimono1,
  2. Noriko Kohyama2,
  3. Toshiro Kamoshida3,
  4. Toshinori Yamamoto4,
  5. Mari Kogo2
  1. 1Department of Pharmacy, Hitachi, Ltd, Hitachi General Hospital, Hitachi, Ibaraki, Japan
  2. 2Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University—Hatanodai Campus, Shinagawa-ku, Tokyo, Japan
  3. 3Department of Medical Gastroenterology, Hitachi, Ltd, Hitachi General Hospital, Hitachi, Ibaraki, Japan
  4. 4Showa University Medical Foundation, Shinagawa-ku, Tokyo, Japan
  1. Correspondence to Mrs Yuka Aimono, Department of Pharmacy, Hitachi, Ltd., Hitachi General Hospital, Hitachi, Ibaraki, Japan; yuka.aimono.cp{at}hitachi.com

Abstract

Objective We investigated factors associated with a reduction in the quality of life and their OR of patients with chronic hepatitis C who underwent ledipasvir/sofosbuvir therapy.

Methods The subjects were 141 outpatients who had undergone ledipasvir/sofosbuvir therapy under a diagnosis of genotype I chronic hepatitis C or Child-Pugh A compensated cirrhosis at Hitachi General Hospital. The patient background before ledipasvir/sofosbuvir therapy, laboratory data and the Chronic Liver Disease Questionnaire scores during ledipasvir/sofosbuvir therapy were investigated. The Chronic Liver Disease Questionnaire consists of 29 questions, and the mean value is calculated as the overall score through a 7-step assessment by patients. Using two divisions: a Chronic Liver Disease Questionnaire score of <7 (symptoms are present) and that of 7 (no symptoms), as objective variables, patients with a Chronic Liver Disease Questionnaire score of <7 were defined as having a reduced quality of life. Independent factors significantly associated with a reduction in the quality of life were extracted using logistic regression analysis.

Results Based on the multivariate analysis, an alanine aminotransferase level of ≥23 U/L (OR: 4.380, 95% CI: 1.394 to 13.756) was extracted as an independent factor associated with a reduction in the quality of life (p<0.05).

Conclusion An increase in the baseline level of alanine aminotransferase was found to play a role in the reduction in the quality of life of patients with chronic hepatitis C who had undergone ledipasvir/sofosbuvir therapy.

  • clinical pharmacy
  • quality in healthcare
  • risk management
  • hepatology
  • side effects of drugs
View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.